A Phase 1 interventional study of Zongertinib in Liver Diseases and Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.
Among the 368 studies in Liver Diseases with a site in United States, this one is the 169th largest by enrollment of the 269 interventional ones that give a count, is one of 10 that started in 2025, is one of 62 in phase 1, and was the 349th registered.
825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:
West Virginia University · Sites in United States
Ages 18+
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
Incyte Corporation · Sites in United States
Ages 18–80
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
368 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 75 · Phase 3 30 · Phase 4 21
First in 1988; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 52 across 522 interventional studies indexed under Liver Diseases.
Median enrollment 48 across the 269 interventional studies, 153 across the 90 observational. Of the 276 that completed or were terminated, 115 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 368 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 7 studies filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
21 of the studies in Liver Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04612764Baylor College of MedicineLiver Disease in Urea Cycle Disorders | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT05264051University of ChicagoMAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease | 2027-03-01 |
| NCT07746999Corey DeStefanoNorth Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health | 2027-03-15 |
Add all 21 to your calendar (.ics) → With an account.
Among the 368 studies in Liver Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m\^2 can take part. Women can only participate if they cannot get pregnant. This study includes people with mild liver problems, people with moderate liver problems, and people without liver problems as a matching control. The purpose of this study is to find out how mild and moderate liver problems affect how the body handles a medicine called zongertinib.
Participants take zongertinib once as tablets. Participants with liver problems are treated in a step-by-step approach with a few days in between for the doctors to review the data and make sure the participants can tolerate the treatment. Participants may continue their regular treatment for their liver problems during the study.
Participants are in the study for about 5 weeks. During this time, they visit the study site 4 times. This also includes an overnight stay for 6 nights. During study visits, the doctors regularly check participants' health and take note of any unwanted effects. To assess the study endpoints, the study staff regularly takes blood samples.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male subjects with Women of child-bearing potential (WOCBP) partner must be willing to use highly effective methods of (condom in combination with other methods or sexual abstinence) from time point of administration of trial medication until 30 days thereafter. These include:
Additionally female partners of male subjects must be willing to use any of the following criteria for a highly effective contraception from at least 30 days before the first administration of the male partner until 30 days thereafter:
Postmenopausal, defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of FSH above 25 U/L and estradiol below 30 ng/L is confirmatory) plus use of condom
exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm comprised participants with mild hepatic impairment classified as Child-Pugh A, who received a single oral dose of 120 mg of zongertinib with 240 mL of water, following an overnight fast of at least 10 hrs.
Drug: Zongertinib
This arm comprised participants with moderate hepatic impairment classified as Child-Pugh B, who received a single oral dose of 120 mg of zongertinib with 240 mL of water, following an overnight fast of at least 10 hrs.
Drug: Zongertinib
This arm comprised all participants with normal hepatic function, individually matched to participants with hepatic impairment according to age, sex, and weight, and who received a single oral dose of 120 milligrams (mg) of zongertinib with 240 milliliters (mL) of water, following an overnight fast of at least 10 hrs.
Drug: Zongertinib
Participants received a single oral dose of 120 milligrams (mg) of zongertinib with 240 milliliters (mL) of water, following an overnight fast of at least 10 hrs
Also known as: BI 1810631, Hernexeos®
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
AUC0-∞ (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 extrapolated to infinity) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
Time frame: Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Maximum Measured Concentration of Zongertinib in Plasma (Cmax)
Cmax (maximum measured concentration of zongertinib in plasma) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
Time frame: Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
AUC0-tz (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 to the last quantifiable data point) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
Time frame: Within 3 hours prior to and 0.50, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120 and 168 hours after administration of zongertinib.
This was a non-randomised, open-label, parallel, individual-matched trial to investigate the effect of mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment on the pharmacokinetics (PK) of zongertinib.
| Milestone | Matched Control | Child-Pugh A | Child-Pugh B |
|---|---|---|---|
| Started | 13 | 8 | 8 |
| Completed | 13 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
AUC0-∞ (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 extrapolated to infinity) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
| hours*nanomoles/Liter (h*nmol/L) | Child-Pugh A | Matched Control to Child-Pugh A | Child-Pugh B | Matched Control to Child-Pugh B |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 31457.80 (26367.83 to 37530.15) | 28490.38 (23880.08 to 33989.26) | 20568.79 (16708.95 to 25318.74) | 24689.75 (20058.33 to 30390.95) |
Cmax (maximum measured concentration of zongertinib in plasma) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
| nanomoles/Liter (nmol/L) | Child-Pugh A | Matched Control to Child-Pugh A | Child-Pugh B | Matched Control to Child-Pugh B |
|---|---|---|---|---|
| Maximum Measured Concentration of Zongertinib in Plasma (Cmax) | 2335.43 (1992.21 to 2737.77) | 2397.44 (2045.10 to 2810.45) | 1322.88 (1077.50 to 1624.09) | 2035.46 (1658.05 to 2498.89) |
AUC0-tz (area under the concentration-time curve of zongertinib in plasma over the time interval from 0 to the last quantifiable data point) is reported. Geometric least squares mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance model (ANOVA) on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. The model included the effects 'degree of hepatic impairment' and 'matched pair' as fixed effects and was fitted separately for the 2 hepatic impaired groups: 1 model for the participants with mild hepatic impairment and their matched controls, and 1 model for the participants with moderate hepatic impairment and their matched controls. These quantities were then back transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint.
| hours*nanomoles/Liter (h*nmol/L) | Child-Pugh A | Matched Control to Child-Pugh A | Child-Pugh B | Matched Control to Child-Pugh B |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 30858.52 (25729.67 to 37008.39) | 27905.66 (23267.20 to 33469.84) | 19956.22 (16097.19 to 24740.58) | 23995.72 (19354.88 to 29747.49) |
Collected over Serious Adverse Events and Other Adverse Events: From study drug administration until end of the residual effect period (i.e. 14 days), up to 336 hours. All-cause mortality: From drug administration till end of trial, up to 18 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Matched Control | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Child-Pugh A | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Child-Pugh B | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Matched Control | Child-Pugh A | Child-Pugh B |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/13 | 0/8 | 1/8 |
Treated set (TS): The treated set included all participants who were treated with at least 1 dose of trial drug. One subject with normal hepatic function could be matched with one subject in one or both groups with hepatic impairment.
| Age, Continuous(Years) | Matched Control | Child-Pugh A | Child-Pugh B | Total |
|---|---|---|---|---|
| Mean | 58.6 ± 6.3 | 62.0 ± 5.9 | 58.9 ± 4.4 | 59.6 ± 5.7 |
| Sex: Female, Male(Participants) | Matched Control | Child-Pugh A | Child-Pugh B | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 1 | 8 |
| Male | 9 | 5 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Matched Control | Child-Pugh A | Child-Pugh B | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 7 | 20 |
| Not Hispanic or Latino | 7 | 1 | 1 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Matched Control | Child-Pugh A | Child-Pugh B | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 12 | 8 | 8 | 28 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Ran from Jan 2025 to primary completion in Jun 2025, 5 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 5 months is below that.
Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zongertinib